Table 3.
Associations between E‐cadherin expression and clinical characteristics or JAG1 expression in cancer cells
| Characteristics | E‐cadherin (Intensity) | P value | E‐cadherin (Proportion) | P value | ||
|---|---|---|---|---|---|---|
| 1 | 2/3 | 1/2/3 | 4/5 | |||
| Total | 39 (25) | 119 (75) | 44 (28) | 114 (72) | ||
| Sex | ||||||
| Male | 22 (56) | 70 (59) | 0.791 | 18 (41) | 48 (42) | 0.891 |
| Female | 17 (44) | 49 (41) | 26 (59) | 66 (58) | ||
| Age (years) | ||||||
| <65 | 18 (46) | 63 (53) | 0.462 | 24 (55) | 57 (50) | 0.608 |
| ≥65 | 21 (54) | 56 (47) | 20 (45) | 57 (50) | ||
| Histologic type | ||||||
| Well differentiated | 17 (44) | 81 (68) | 0.007** | 20 (45) | 78 (68) | 0.008** |
| Others | 22 (56) | 38 (32) | 24 (55) | 36 (32) | ||
| T stage | ||||||
| T1, 2 | 1 (3) | 44 (37) | <0.001** | 4 (9) | 41 (36) | <0.001** |
| T3, 4 | 38 (97) | 74 (63) | 40 (91) | 72 (64) | ||
| Unknown | 1 | 1 | ||||
| Lymph node metastasis | ||||||
| Negative | 15 (38) | 72 (61) | 0.014* | 19 (43) | 68 (60) | 0.055 |
| Positive | 24 (62) | 46 (39) | 25 (57) | 45 (40) | ||
| Unknown | 1 | 1 | ||||
| Stage of tumor | ||||||
| 0/I/II | 10 (26) | 68 (57) | <0.001** | 13 (30) | 65 (57) | 0.002** |
| III/IV | 29 (74) | 51 (43) | 31 (70) | 49 (43) | ||
| Lymphatic invasion | ||||||
| Negative | 18 (46) | 86 (72) | 0.003** | 23 (52) | 81 (71) | 0.028* |
| Positive | 21 (54) | 33 (28) | 21 (48) | 33 (29) | ||
| Venous invasion | ||||||
| Negative | 15 (38) | 77 (65) | 0.004** | 21 (48) | 71 (62) | 0.100 |
| Positive | 34 (62) | 42 (35) | 23 (52) | 43 (38) | ||
| JAG1 (Cancer) | ||||||
| Weak | 11 (28) | 40 (34) | 0.527 | 14 (32) | 37 (32) | 0.939 |
| Moderate/Strong | 28 (72) | 79 (66) | 30 (68) | 77 (68) | ||
| Weak/moderate | 26 (67) | 82 (69) | 0.795 | 24 (55) | 84 (74) | 0.023* |
| Strong | 13 (33) | 37 (31) | 20 (45) | 30 (26) | ||
χ2‐test: *P < 0.05, **P < 0.01. Each value is presented as number (%) of specimens.